A Review on the HPLC Method Development and Validation Studies of Combined Dosage Form of Rosuvastatin and Ezetimibe
DOI:
https://doi.org/10.22270/ajprd.v12i4.1449Abstract
Analytical method development is an important aspect of drug development and manufacturing. An exceptional analytical method is the one which detects the active pharmaceutical ingredients as well as the impurities and other chemical entities which invariably enters the formulations due to various reasons. The methods which are developed accordingly are to be validated as per the ICH guidelines so as to be accepted in a commercial setting. Coronary Artery Disease is a life threatening condition, which affects millions of people, where the blood flow to the heart is affected due to plaque deposits. Patients are administered with combined dosages of Rosuvastatin and Ezetimibe for the effective treatment and management of the disease. Various pharmaceutical formulations are available with the combined dosage forms and analytical method development is necessary during the development of the drug so as to detect impurities and ascertain safety and efficacy. HPLC is the most effective and reliable methodology for the analysis of the pharmaceutical drug dosages which are released to the market by pharmaceutical companies. The review focus on the various methodologies developed over the years to effectively analyse the combined drug formulations of Rosuvastatin and Ezetimibe as per the ICH guidelines.
Downloads
References
Mctaggart F, Buckett L, Davidson R, Holdgate G, Mccormick A, Schneck D. et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87(5A):28B–32B. DOI:10.1016/S0002-9149(01)01454-0.
Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol. 2012;6:17-33. doi: 10.4137/CMC.S4324. Epub 2012 Feb 1. PMID: 22442638; PMCID: PMC3303484.
Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet . 2005;44(5):467–94. doi: 10.2165/00003088-200544050-00002.
Knopp RH, Bayes H, Manion CV, Lipka LJ, Melani L, LeBeaut AP. et al. Effect of ezetimibe on serum concentrations of lipid soluble vitamins. Atherosclerosis. 2001;2(2):90. doi: 10.1016/s0195-668x(02)00807-2.
P.S.R.Ch.N.P. Varma, A. Lakshmana Rao and S.C. Dinda. Development and Validation of Stability Indicating RP-Hplc Method for Simultaneous Estimation of Rosuvastatin and Ezetimibe in Combined Tablet Dosage Form. RasayanJ.Chem. 2012; 5(3):269-279.
SumanLamichhane, Bhaswati Das, Rudra Prasad Adhikari1, Mari RajuJeyaprakash. Overview of Forced Degradation Analysis for FDA Approved Antiretroviral agents: A Review. Journal of Young Pharmacists. 2022; 14(3):273-282.
Anita R. P., Milind J. U., Krishna R. G. Genotoxic Impurities: An Important Regulatory Aspect. Asian J Pharm Clin Res.2022;13 (6):0-25. DOI: 10.22159/ajpcr.2020.v13i6.37370.
Anuradha K. Gajjar and Vishal D. Shah. Development and Validation of a Stability-Indicating Reversed-Phase HPLC Method for Simultaneous Estimation of Rosuvastatin and Ezetimibe from Their Combination Dosage Forms. Eurasian J. Anal. Chem. 2010; 5(3):280-298.
Varghese SJ, Ravi TK. Determination of rosuvastatin and ezetimibe in a combined tablet dosage form using high-performance column liquid chromatography and high-performance thin-layer chromatography. J AOAC Int. 2010; (4):1222-7. PMID: 20922955. DOI:10.1093/jaoac/93.4.1222.
P.S.R.Ch.N.P. Varma, A. Lakshmana Rao, and S.C. Dinda. Development and Validation of Stability Indicating RP-HPLC Method for Simultaneous Estimation of Rosuvastatin and Ezetimibe in combined tablet dosage form. Rasayan J. of Chem. 2012; 5(3):269-279.
Mathrusri Annapurna Mukthinuthalapati, V. Bukkapatnam, Sailaja Bandaru. Stability indicating liquid chromatographic method for the simultaneous determination of rosuvastatin and ezetimibe in pharmaceutical formulations. Adv Pharm Bull. 2014;4(4):405–411. doi: 10.5681/apb.2014.060.
Vadthya Rajashekar, K. Rajeswar Dutt, N. Ramathilagam. RP-HPLC Method Development and Validation for the Simultaneous Estimation of Rosuvastatin and Ezetimibe in Tablet Dosage Form. Department of Pharmaceutical Analysis and Quality Assurance. IJPAR. 2014; 3(1):13-19.
D, S. S., H. K. T, V. P. Rao K, and S. R. Y. Validated Rp-Hplc Method For Simultaneous Determination Of Rosuvastatin Calcium And Ezetimibe In Pharmaceutical Dosage Form. International Journal of Pharmacy and Pharmaceutical Sciences. 2015; 7(4):209 DOI:https://journals.innovareacademics.in/index.php/ijpps/article/view/3989.
T. Hemant Kumar and D. GowriSankar. Simultaneous estimation of rosuvastatin calcium and ezetimibe in pharmaceutical formulation by RP-HPLC method with forced degradation studies. Der Pharmacia Lettre. 2016; 8(6):288-298.
Anil ShahajiKhile, N. Gayatri Devi, M. Subba Rao and D. Ramachandran. Development and Validation of RP-LC Method For Simultaneous Estimation of Rosuvastatin And Ezetimibe In Bulk and Its Pharmaceutical Formulations. Am. J. PharmTech Res. 2017; 7(2).
Padmanabh Deshpande and Amit Gunge. Simultaneous Estimation of Rosuvastatin Calcium and Ezetimibe as Bulk Drug and In Tablet Dosage Form by RP-HPLC Method. Indo Am. J. P. Sci. 2018; 05(04). DOI: doi.org/10.5281/zenodo.1239783.
Patel Aesha A. and Dr. Paresh Patel. Development and Validation of Stability Indicating RP-HPLC method for Estimation of Rosuvastatin and Ezetimibe in Capsule Dosage Form. World Journal of Pharmaceutical Research. 2018; 7(7):1502-1516.
Kurbanoglu S, Esim O, KoseOzkan C, Savaser A, Ozkan Y, Uslu B, et al. Stability Indicating Liquid Chromatographic Method for the Simultaneous Determination of Rosuvastatin and Ezetimibe from Pharmaceuticals and Biological Samples. JOTCSA. 2020; 7(3):865–74. DOI: https://doi.org/ 10.18596/jotcsa.788227.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Sajith Kumar Chandran Chandran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.